Home > Haematology > EHA 2019 > Lymphoid Malignancies > ASCEND study: Acalabrutinib improves progression-free survival in relapsed/refractory CLL

ASCEND study: Acalabrutinib improves progression-free survival in relapsed/refractory CLL

Expert
Dr Paolo Ghia, Vita-Salute San Raffaele University, Italy
Conference
EHA 2019
Trial
Phase 3, ASCEND

Dr Paolo Ghia (Vita-Salute San Raffaele University, Italy) presented the findings from the phase 3 ASCEND study of the Bruton’s tyrosine Kinase inhibitor (BTKi) acalabrutinib in relapsed or refractory chronic lymphocytic leukaemia (CLL). The study demonstrated that acalabrutinib had superior progression-free survival vs rituximab with idelalisib or bendamustine [1].

The ASCEND trial was a global, multicentre, open-label, phase 3 study that randomised 310 patients to receive either acalabrutinib monotherapy or the physician’s choice of either idelalisib plus rituximab or bendamustine.. Acalabrutinib is a highly selective, potent inhibitor of BTK that has previously demonstrated substantial activity and improved tolerability in patients with CLL, similar to ibrutinib. In this study, acalabrutinib monotherapy significantly improved progression-free survival, with a more tolerable safety profile, co...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on